BARNES-JEWISH HOSPITAL
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
About Us
News & Events
Maps & Locations
Contact Us
Google Search
PATIENT AND VISITOR INFORMATION
TREATMENT PROGRAMS
PREVENTION AND SCREENING
RESEARCH
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Home
Content Block Control
Share
NEW SEARCH
RETURN TO SEARCH RESULTS
Number:
GOG 131H
Principal Investigator:
Mutch, David
Title:
A Phase II Evaluation of Ixabepilone In The Treatment of Recurrent Or Persistent Leiomyosarcoma Of The Uterus
Phase:
II
Disease Site:
Corpus Uterus
Participating Site(s):
Contact:
800-600-3606 or
info@ccadmin.wustl.edu
Description:
The purpose of this study is to find out if the study drug, Ixabepilone, works in treating your type of cancer and to find out what side effects are caused by treatment with this drug.
The drug ixabepilone has been approved by the FDA (Food and Drug Administration) for use in patients with breast cancer, but is considered experimental for your type of cancer. Ixabepilone is a drug called an epothilone. Epothilones are similar to paclitaxel (a common chemotherapy drug), but have the potential to work in cells that are resistant to paclitaxel. Ixabepilone has caused tumors to shrink or stop growing for a period of time in previous studies
More Information:
(Links will take you off this web site)
Internal Protocol Documents (requires Siteman administrative database password)